A nontoxic pain killer designed by modeling of pathological receptor conformations

  title={A nontoxic pain killer designed by modeling of pathological receptor conformations},
  author={Viola Spahn and Giovanna Del Vecchio and Dominika Labuz and Antonio Rodr{\'i}guez-Gaztelumendi and Nicolas Massaly and Julia Temp and Vedat Durmaz and Peggy Sabri and Marco Reidelbach and Halina Machelska and M. Weber and Christoph Stein},
  pages={966 - 969}
A pain killer without side effects Opioids are very strong and effective pain killers. However, they also have a range of well-known side effects and can cause addiction. Painful conditions such as inflammation or trauma are often associated with localized tissue acidification. Spahn et al. designed a novel opioid receptor agonist that, unlike clinically used opioids, best activates the receptors in such acidified tissues. In rat models of inflammatory pain, the new drug exerted strong pain… 
Opioid receptor signaling, analgesic and side effects induced by a computationally designed pH-dependent agonist
The hypothesis that a ligand’s pKa should be close to the pH of injured tissue to obtain analgesia without side effects is supported.
Polyglycerol-opioid conjugate produces analgesia devoid of side effects
PG-M may serve as prototype of a peripherally restricted opioid formulation designed to forego central and intestinal side effects and to selectively release morphine in injured tissue and to prevent blood-brain barrier permeation.
pKa of opioid ligands as a discriminating factor for side effects
It is reported that a new double-fluorinated compound (FF6) and fentanyl show similar pKa, MOR affinity and [35S]-GTPγS binding at low and physiological pH values.
A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance
It is demonstrated that MCC22 provides highly potent analgesia and improved functional outcomes in a model of inflammatory arthritis, without inducing typical opioid tolerance, as well as minimizing the risks typically associated with chronic opioid use.
Recent Advances in Peripheral Opioid Receptor Therapeutics
The goal of this paper is to identify and elaborate on recent advances in peripheral opioid receptor therapeutics of pH-sensitive opioid ligands and limiting opioid permeability across the blood-brain barrier.
Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.
This hypothesis is that addiction caused by MOR-targeting analgesics could be blocked by blending in a new "antiaddiction" ingredient that does not diminish analgesia and does not introduce its own therapeutically limiting side effects, then continued clinical use of prescription opioids for treating pain could be maintained (or even enhanced) instead of curtailed.
Analgesic effects of a novel pH-dependent μ-opioid receptor agonist in models of neuropathic and abdominal pain
It is shown that NFEPP exerts peripheral opioid receptor–mediated analgesia exclusively in damaged tissue in models of neuropathic and abdominal pain, and pH significantly dropped both at injured nerves after chronic constriction injury and in the abdominal cavity after acetic acid administration.
Uncovering the analgesic effects of a pH-dependent mu-opioid receptor agonist using a model of non-evoked ongoing pain.
It is demonstrated that low, but not higher doses of NFEPP produce conditioned place preference but not constipation or motor disturbance, in contrast to fentanyl, and a peripherally restricted antagonist is provided to provide evidence thatNFEPP-induced place preference is mediated by peripheral opioid receptors.
Advances in Achieving Opioid Analgesia Without Side Effects
A critical overview of emerging opioid-based strategies aimed at effective pain relief and improved side effect profiles is provided, including biased agonism and several promising novel opioids comprehensively examined in preclinical studies.


Crystal structure of the μ-opioid receptor bound to a morphinan antagonist
The 2.8 Å crystal structure of the mouse µ-OR in complex with an irreversible morphinan antagonist is described, revealing high-resolution insights into opioid receptor structure that will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.
The K+ channel GIRK2 is both necessary and sufficient for peripheral opioid-mediated analgesia
GIRK channels, major effectors for opioid signalling in the CNS, are absent from mouse peripheral sensory neurons but present in human and rat and a regulatory element in the rat GIRK2 gene accounts for differential expression in rodents.
Functional Characteristics of the Naked Mole Rat μ-Opioid Receptor
Minor functional differences between rat and NMR MOR are found suggesting that other differences e.g. in anatomical distribution of MOR underlie the NMR's extreme reaction to opioids.
Opioid Receptors
Genotyping of opioid receptors is still in its infancy and a relevant progress can be achieved by using advanced gene sequencing techniques described in this review that allow the researchers to obtain vast quantities of data on human genomes and transcriptomes in a brief period of time and with affordable costs.
Mu Opioid Receptors on Primary Afferent Nav1.8 Neurons Contribute to Opiate-Induced Analgesia: Insight from Conditional Knockout Mice
It is genetically demonstrated for the first time that mu opioid receptors partly mediate opiate analgesia at the level of Nav1.8-positive sensory neurons, which is feasible targets to alleviate some forms of persistent pain.
Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor.
Modulation of Transient Receptor Vanilloid 1 Activity by Transient Receptor Potential Ankyrin 1
This study shows sensitization of TRPV1 via activation of TRPA1, which involves adenylyl cyclase, increased cAMP, subsequent translocation and activation of PKA, and phosphorylation of TRpV1 at PKAosphorylation residues, which suggests that cross-sensitization ofTRP channels contributes to enhanced pain sensitivity in inflamed tissues.
Propagation of conformational changes during μ-opioid receptor activation
The results suggest that one or both of these domains may play a role in the initial interaction with the G protein, and that TM5 and TM6 are only engaged later in the process of complex formation, as has been suggested for other family A G-protein-coupled receptors.
Differentiation of δ, μ, and κ opioid receptor agonists based on pharmacophore development and computed physicochemical properties
Compounds that bind with significant affinity to the opioid receptor types, δ, μ, and κ, with different combinations of activation and inhibition at these three receptors could be promising